SynthesisNeurosurgical review2025
Frailty evaluation for predicting the survival in patients with glioma: a meta-analysis.
Synthesis in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrailty, a multidimensional syndrome associated with decreased physiological reserve, may influence survival outcomes in patients with glioma. This meta-analysis aimed to evaluate the association between frailty and survival outcomes in glioma patients, with implications for nursing and clinical practice.
methodsThis meta-analysis included cohort studies investigating frailty and survival in glioma patients. Comprehensive searches were conducted in PubMed, Embase, and Web of Science up to October 2024. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Sensitivity analyses using a leave-one-out approach were performed to evaluate the robustness of the finding. Subgroup and meta-regression analyses were performed to evaluate the influence of study characteristics on the outcome.
resultsEleven cohort studies involving 2,519 patients were included. Frailty was significantly associated with poorer overall survival (OS) in glioma patients (HR: 1.47, 95% CI: 1.25-1.74, p < 0.001) with moderate heterogeneity (p for Cochrane Q test = 0.12, I² = 35%). Subgroup analyses revealed consistent results across tumor grades (p = 0.92), primary treatments (p = 0.82), age groups (p = 0.14), proportion of men (p = 0.23), frailty assessment methods (p = 0.43), follow-up durations (p = 0.25), analytic models (p = 0.30), and study quality scores (p = 0.21). Meta-regression did not show a significant influence of sample size, mean age, sex, follow-up duration, or study quality score on the association (p all > 0.05). Frailty was also associated with shorter progression-free survival (HR: 1.20, 95% CI: 1.06-1.36, p = 0.004) with mild heterogeneity (p for Cochrane Q test = 0.41, I² = 0%).
conclusionFrailty appears to be a significant predictor of poorer survival in glioma patients, underscoring its importance in clinical decision-making and patient care. Integrating frailty assessments into nursing and treatment protocols could improve outcome predictions and tailored interventions.
Indexed as
Identifiers
40637871What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.